Immunotoxicity of nitrobenzene in female B6C3F1 mice.
Nitrobenzene (NBZ) is primarily employed as an oxidizing agent in the synthesis of analine and benzene compounds. It produces myelotoxic effects and effects on erythrocytes in both animal models and man. Reported hepatosplenomegaly and effects on the bone marrow are indicators that NBZ may be immunotoxic. In these studies, female B6C3F1 mice were exposed to 30, 100 and 300 mg/kg of NBZ in corn oil by gavage for 14 consecutive days. To assess the immunotoxic potential of NBZ, body and organ weights were determined and selected immunologic and host resistance responses were studied. In these studies, the liver and spleen appeared to be the primary target organs. Both liver and spleen weights were dose dependently increased. Gross histopathologic examinations revealed significant changes in the spleen, consisting of severe congestion of the red pulp areas with erythrocytes and reticulocytes. Serum chemistry profiles showed increases in alanine aminotransferase and aspartate aminotransferase activities, indicating liver toxicity. Hematologic studies showed a decrease in erythrocyte number and a concomitant increase in mean corpuscular hemoglobin and mean corpuscular volume. A dose-dependent increase in peripheral reticulocytes was also seen. DNA synthesis was enhanced, as was the number of formed elements and the number of monocyte/granulocyte stem cells in the bone marrow of treated mice. IgM responses were decreased and the phagocytic activity of macrophages in the liver was dose dependently increased with a concomitant decrease in the activities in the spleen and lung. Other immunological parameters examined were unchanged. Host resistance to microbial or viral infection was not markedly altered by NBZ; however, there were trends towards increased susceptibility where T-cell function contributes to host defense. These data indicate that NBZ-induced hemolysis and liver injury are linked to the observed alterations in bone marrow activity.
Burns
L A
LA
Department of Pharmacology, Medical College of Virginia/Virginia Commonwealth University, Richmond 23298.
Bradley
S G
SG
White
K L
KL
McCay
J A
JA
Fuchs
B A
BA
Stern
M
M
Brown
R D
RD
Musgrove
D L
DL
Holsapple
M P
MP
Luster
M I
MI
D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004342:Drug Hypersensitivity; D004912:Erythrocytes / Q000187:drug effects; D005260:Female; D016867:Immunocompromised Host / Q000187:drug effects / Q000276:immunology; D007239:Infections / Q000276:immunology; D007694:Killer Cells, Natural / Q000187:drug effects; D008099:Liver / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008546:Melanoma, Experimental / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009578:Nitrobenzenes / Q000008:administration & dosage / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D011897:Random Allocation; D013154:Spleen / Q000166:cytology / Q000187:drug effects*; D013601:T-Lymphocytes / Q000187:drug effects
D009578:Nitrobenzenes